Vimarsana
Biggest News Aggregation in the World

Page 22 - Clinical Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Sciences Today - Breaking & Trending Today

Regeneron to Highlight Scientific Advancements Across - Vimarsana News

Regeneron to Highlight Scientific Advancements Across

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse...

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH - Vimarsana News

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations...

Baby blues can happen as early as first trimester: Study - Vimarsana News

Baby blues can happen as early as first trimester: Study

The findings underscore the need for more early intervention during pregnancy, said researchers. Read more at straitstimes.com.

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - Vimarsana News

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale total score vs....

Positive Topline Results Reported for Phase 3 Clinical Trial Evaluating Schizophrenia Treatment - Vimarsana News

Positive Topline Results Reported for Phase 3 Clinical Trial Evaluating Schizophrenia Treatment

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.